Sana Biotechnology, Inc. Payments for Tenant Improvements
Sana Biotechnology, Inc. (SANA) reported Payments for Tenant Improvements of $5.45 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForTenantImprovements · last filed 2022-03-16
- Sana Biotechnology, Inc. payments for tenant improvements for the quarter ending 2021-12-31 was $285.00K.
- Sana Biotechnology, Inc. payments for tenant improvements for the quarter ending 2021-09-30 was $1.77M.
- Sana Biotechnology, Inc. payments for tenant improvements for the quarter ending 2020-12-31 was $0.00.
- Sana Biotechnology, Inc. payments for tenant improvements for the quarter ending 2020-09-30 was $0.00.
- Sana Biotechnology, Inc. payments for tenant improvements for fiscal 2021 was $5.45M, a 5883.52% increase from fiscal 2020.
- Sana Biotechnology, Inc. payments for tenant improvements for fiscal 2020 was $91.00K, a 98.40% decline from fiscal 2019.
- Sana Biotechnology, Inc. payments for tenant improvements for fiscal 2019 was $5.70M.
| Period end | Payments for Tenant Improvements 3 month | Payments for Tenant Improvements 6 month | Payments for Tenant Improvements 9 month | Payments for Tenant Improvements 12 month |
|---|---|---|---|---|
| 2021-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $2.06M derived: sum of 2 quarters · filed 2022-03-16 | $5.45M 10-K · filed 2022-03-16 | |
| 2021-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $5.16M 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $3.39M 10-Q · filed 2021-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $0.00 derived: sum of 2 quarters · filed 2022-03-16 | $91.00K 10-K · filed 2022-03-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $91.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $91.00K 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $5.70M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |